Drug Assignments

 

Drug Name Active Ingred Mfr Indication Approval
Date
AHFS Class NDA
Chem
Type*
Appl No
Arymo ER® morphine sulfate Egalet severe pain requiring daily, around-the-clock, long-term opioid treatment 2017/01/09 28:08.08 - Opiate Agonists 5S 208603
Nitrous Oxide nitrous oxide Matheson Tri-Gas general anesthesia; analgesia 2017/01/09 28:04.16 - Inhalation Anesthetics 209989
Esbriet® pirfenidone Genentech idiopathic pulmonary fibrosis (IPF) 2017/01/11 48:02 - Antifibrotic Agents 3S 208780
Vantrela ER® hydrocodone Teva pain 2017/01/17 28:08.08 - Opiate Agonists 3S 207975
Rhofade® oxymetazoline Allergan persistent facial erythema associated with rosacea 2017/01/18 84:92 - Skin and Mucous Membrane Agents, Misc 10S 208552
Trulance® plecanatide Synergy chronic idiopathic constipation (CIC) 2017/01/19 56:92 - GI Drugs, Miscellaneous 1S 208745
Tepadina® thiotepa Adienne SA reduce risk of graft rejection; adenocarcinoma of the breast or ovary; superficial papillary carcinoma of the urinary bladder; controlling intracavitary effusions 2017/01/26 10:00 - Antineoplastic Agents 5S 208264
ArmonAirTM Respiclick® fluticasone propionate Teva asthma 2017/01/27 68:04 - Adrenals 5S 208798
AirDuoTM Respiclick® fluticasone propionate; salmeterol Teva asthma 2017/01/27 68:04 - Adrenals; 12:12.08.12 - Selective beta-2-Adrenergic Agonists 4S 208799
Corphedra® ephedrine Par anesthesia-induced hypotension 2017/01/27 12:12.12 - alpha- and beta-Adrenergic Agonists 5S 208943
Parsabiv® etelcalcetide Kai secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis 2017/02/07 92:92 - Other Miscellaneous Therapeutic Agents 1S 208325
Emflaza® deflazacort Marathon Duchenne muscular dystrophy (DMD) 2017/02/09 68:04 - Adrenals 1P 208684
Siliq® brodalumab Valeant plaque psoriasis 2017/02/15 84:92 - Skin and Mucous Membrane Agents, Misc 761032
Qtern® dapagliflozin; saxagliptin AstraZeneca type 2 diabetes mellitus 2017/02/27 68:20.18 - SGLT-2 Inhibitors; 68:20.05 - DPP-4 Inhibitors 4S 209091
Xermelo® telotristat ethyl Lexicon Pharma carcinoid syndrom diarrhea 2017/02/28 56:08 - Antidiarrhea Agents 1S 208794
Noctiva® desmopressin acetate Serenity nocturnal polyuria 2017/03/03 68:28 - Pituitary 5S 201656
Kisqali® ribociclib Novartis HR+/HER2- advanced or metastatic breast cancer 2017/03/13 10:00 - Antineoplastic Agents 1P 209092
Xadago® safinamide Newron Parkinson's disease 2017/03/21 28:36.32 - Monoamine Oxidase B Inhibitors 1S 207145
Symproic® naldemedine Shionogi opioid-induced constipation (OIC) 2017/03/23 56:92 - GI Drugs, Miscellaneous 1S 208854
Bavencio® avelumab EMD Serono metastatic Merkel cell carcinoma (MCC) 2017/03/23 10:00 - Antineoplastic Agents 761049
Zejula® niraparib Tesaro epithelial ovarian, fallopian tube, or primary peritoneal cancer 2017/03/27 10:00 - Antineoplastic Agents 1P 208447
Dupixent® dupilumab Regeneron moderate-to-severe eczema (atopic dermatitis) 2017/03/28 84:92 - Skin and Mucous Membrane Agents, Misc 1 761055
Ocrevus® ocrelizumab Genentech relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) 2017/03/28 92:20 - Immunomodulatory Agents 1 761053
Odactra® house dust mites (HDM) allergen extract MSD HDM-induced allergic rhinitis 2017/03/01 80:02 - Allergenic Extracts 125592
Austedo® deutetrabenazine Teva Huntington's chorea, tardive dyskinesia 2017/04/03 28:92 - Central Nervous System Agents, Misc 1S 208082
Ingrezza® valbenazine Neurocrine Biosciences tardive dyskinesia 2017/04/11 28:92 - Central Nervous System Agents, Misc 1P 209241
Roxybond® oxycodone Inspirion pain 2017/04/20 28:08.08 - Opiate Agonists 5P 209777
Renflexis® infliximab-abda Samsung Bioepsis Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis 2017/04/21 92:36 - Disease-modifying Antirheumatic Drugs 761054
Xatmep® methotrexate Silvergate acute lymphoblastic leukemia (ALL) in pediatric patients; active polyarticular juvenile idiopathic arthritis (pJIA) 2017/04/25 10:00 - Antineoplastic Agents 3S 208400
Brineura® cerliponase alfa Biomarin indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency. 2017/04/27 44:00 - Enzymes 761052
Rydapt® midostaurin Novartis acute myeloid leukemia (AML) that is FLT3 mutation-positive; aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia 2017/04/28 10:00 - Antineoplastic Agents 1P 207997
Tymlos® abaloparatide Radius postmenopausal women with osteoporosis at high risk for fracture 2017/04/28 68:24 - Parathyroid 1/4S 208743
Alunbrig® brigatinib Ariad anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) 2017/04/28 10:00 - Antineoplastic Agents 1P 208772
Imfinzi® durvalumab AstraZeneca locally advanced or metastatic urothelial carcinoma 2017/05/01 10:00 - Antineoplastic Agents 761069
Steritalc® talc Novatech decrease the recurrence of malignant pleural effusions and pneumothorax 2017/05/01 24:16 - Sclerosing Agents 5S 205555
Kisqali® Femara® Co-Pack letrozole; ribociclib Novartis hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer 2017/05/04 10:00 - Antineoplastic Agents 4S 209935
Radicava® edaravone MT Pharma amyotrophic lateral sclerosis (ALS) 2017/05/05 28:92 - Central Nervous System Agents, Miscellaneous 1 209176
Minolira® minocycline hydrochloride Dr Reddy's moderate to severe acne vulgaris 2017/05/08 84:92 - Skin and Mucous Membrane Agents, Misc 5S 209269
Jadenu® deferasirox Novartis chronic iron overload 2017/05/08 64:00 - Heavy Metal Antagonists 5S 207968
Kevzara® sarilumab Sanofi adult rheumatoid arthritis 2017/05/23 92:36 - Disease-modifying Antirheumatic Drugs 1 761037
Zerviate® cetirizine hydrochloride Nicox ocular itching associated with allergic conjunctivitis 2017/05/30 52:02 - Antiallergic Agents 3P 208694
Rebinyn® factor IX (recombinant), glycoPEGylated
[nonacog beta pegol]
Novo Nordisk hemophilia B for on-demand treatment and control of bleeding episodes and for perioperative management of bleeding 2017/05/31 20:28.16 - Hemostatics 1 125611
Gleolan® aminolevulinic acid oral solution NX optical imaging 2017/06/06 3P 208630
Fibryna® fibrinogen (human) Octapharma afibrinogenemia and hypofibrinogenemia 2017/06/07 20:28.16 - Hemostatics 1 125612
Baxdela® delafloxacin Melinta acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria 2017/06/19 8:12.18 - Quinolones 1S 208610
Haegarda® C1 esterase inhibitor (human) CSL Behring prophylaxis of hereditary angioedema (HAE) 2017/06/22 92:32 - Complement Inhibitors 1O 125606
Bevyxxa® betrixaban Portola prophylaxis of venous thromboembolism (VTE) 2017/06/23 20:12.04.14 - Direct Factor Xa Inhibitors 1S 208383
Triptodur® Kit triptorelin Arbor central precocious puberty 2017/06/29 68:18 - Gonadotropins 5S/O 208956
Endari® L-glutamine Emmaus reduce acute complications associated with sickle cell disease 2017/07/07 92:92 - Other Miscellaneous Therapeutic Agents 5S 208587
Tremfya® guselkumab Janssen moderate-to-severe plaque psoriasis 2017/07/13 84:92 - Skin and Mucous Membrane Agents, Miscellaneous 761061
Zypitamag® pitavastatin magnesium Zydus primary hyperlipidemia or mixed dyslipidemia 2017/07/14 24:06.08 - HMG-CoA Reductase Inhibitors 2 208379
Nerlynx® neratinib Puma early stage HER2-overexpressed/amplified breast cancer 2017/07/17 10:00 - Antineoplastic Agents 1S 208051
Vosevi® sofosbuvir; velpatasvir; voxilaprevir Gilead hepatitis C virus (HCV) infection 2017/07/18 8:18.40.16 - HCV Polymerase Inhibitors 1,4P 209195
Lusduna® insulin glargine Merck Sharp Dohme type 1 or 2 diabetes mellitus 2017/07/19 68:20.08 - Insulins 5S 208722
Nityr® nitisinone Cycle Pharms hereditary tyrosinemia type 1 (HT-1) 2017/07/26 92:92 - Other Miscellaneous Therapeutic Agents 5S 209449
Idhifa® enasidenib Celgene acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation 2017/08/01 10:00 - Antineoplastic Agents 1P 209606
Vyxeos® daunorubicin liposomal; cytarabine Celator therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) 2017/08/03 10:00 - Antineoplastic Agents 4S 209401
Mavyret® glecaprevir; pibrentasvir Abbvie hepatitis C virus (HCV) infection 2017/08/03 8:18.40.20 - HCV Protease Inhibitors; 8:18.40.24 - HCV Replication Complex Inhibitors 1,4P 209394
Carospir® spironolactone CMP heart failure, hypertension, edema 2017/08/04 24:32.20 - Mineralocorticoid (Aldosterone) Receptor Antagonists 3S 209478
Nikita® pitavastatin Lupin dyslipidemias 2017/08/04 24:06.08 - HMG-CoA Reductase Inhibitors 2S 209478
Lynparza® olaparib AstraZeneca ovarian cancer 2017/08/17 10:00 - Antineoplastic Agents 3P 208558
Drax Exametazime drax exametazime Jubilant leukocyte (white blood cell) labeled scintigraphy as an adjunct in the localization of intraabdominal infection and inflammatory bowel disease 2017/08/17 36:68 - Roentgenography 5S 208870
Besponsa® inotuzumab Wyeth relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) 2017/08/17 10:00 - Antineoplastic Agents 1O 761040
Duzallo® lesinurad; allopurinol Ardea hyperuricemia associated with gout 2017/08/18 40:40 - Uricosuric Agents; 92:16 - Antigout Agents 4S 209203
Gocovri® amantadine Adamas dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy 2017/08/24 28:36.04 - Adamantanes 3S/O 208944
Cyltezo® adalimumab-adbm Boehringer Ingelheim rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulerative colitis (UC), plaque psoriasis (Ps) 2017/08/25 92:36 - Disease-modifying Antirheumatic Drugs, 92:20 - Immunomodulatory Agents, 56:92 - GI Drugs, Misc 761058
benznidazole benznidazole Chemo Research Chagas disease (American trypanosomiasis) 2017/08/29 8:30.92 - Antiprotozoals, Misc 1P/O 209570
Vabomere® meropenem; vaborbactam Rempex complicated urinary tract infections (cUTI) 2017/08/29 8:12.07.08 - Carbapenems 1/4P 209776
Kymriah® tisagenlecleucel Novartis B-cell precursor acute lymphoblastic leukemia (ALL) 2017/08/30 26:12 - Gene Therapy (new class); 10:00 - Antineoplastic Agents 1 125646
Admelog® insulin lispro Sanofi Aventis diabetes mellitus 2017/09/01 68:20.08 - Insulins 5S 209196
Mylotarg® gemtuzumab Wyeth acute myeloid leukemia (CD33+ AML) 2017/09/01 10:00 - Antineoplastic Agents 761060
Aliqopa® copanlisib Bayer relapsed follicular lymphoma (FL) 2017/09/14 10:00 - Antineoplastic Agents 209936
Mvasi® bevacizumb-awwb Amgen metastatic colorectal cancer; non-squamous non-small cell lung cancer; glioblastoma; metastatic renal cell carcinoma; cervical cancer 2017/09/14 10:00 - Antineoplastic Agents 761028
Adzenys® ER amphetamine Neos attention deficit hyperactivity disorder (ADHD) 2017/09/15 28:20.04 - Amphetamines 3S 204325
Solosec® secnidazole Symbiomix bacterial vaginosis 2017/09/15 8:30.92 - Antiprotozoals, Misc 1P 209363
Xhance® fluticasone propionate Optnose rhinitis 2017/09/18 52:08.08 - Corticosteroids 5S 209022
Trelegy Ellipta® fluticasone furoate; umeclidinium; vilanterol GlaxoSmithKline chronic obstructive pulmonary disease (COPD) 2017/09/18 68:04 - Adrenals; 12:08.08 - Antimuscarinics/Antispasmodics; 12:12.08.12 - Selective beta-2-Adrenergic Agonists 5S 209022
Clorotekal® chloroprocaine Sintetica spinal anesthesia 2017/09/26 72:00 - Local Anesthetics 5S 208791
Verzenio® abemaciclib Eli Lilly HR+,HER2- advanced or metastatic breast cancer 2017/09/28 10:00 - Antineoplastic Agents 1S 208716
Fiasp® insulin aspart Novo Nordisk diabetes 2017/09/29 68:20.08 - Insulins 5S 208751
Ascor® ascorbic acid McGuff scurvy 2017/10/02 88:12 - Vitamin C 7S 209112
Zilretta® triamcinolone acetonide Flexion osteoarthritis knee pain 2017/10/06 68:04 - Adrenals 5S 208845
Lyrica CR® pregabalin Pfizer neuropathic pain associated with diabetic peripheral neuropathy (DPN); postherpetic neuralgia (PHN) 2017/10/11 28:12.92 - Anticonvulsants, Misc; 28:40 - Fibromyalgia Agents; 28:08.92 - Analgesics and Antipyretics, Misc 5S 209501
Yescarta® axicabtagene ciloleucel Kite certain types of non-Hodgkin lymphoma (NHL) 2017/10/18 26:12 - Gene Therapy; 10:00 - Antineoplastic Agents 1P/O 125643
Shingrix® zoster vaccine recombinant GSK shingles (herpes zoster) vaccine 2017/10/20 80:12 - Vaccines 1S 125614
Prexxartan® valsartan Carmel hypertension; heart failure 2017/10/30 24:32.08 - Angiotensin II Receptor Antagonists 3S 209139
Calquence® acalabrutinib Acerta mantle cell lymphoma (MCL) 2017/10/31 10:00 - Antineoplastic Agents 1P 210259
Vyzulta® latanoprostene bunod Valeant open-angle glaucoma or ocular hypertension 2017/11/02 52:40.28 - Prostaglandin Analogs 1 207795
Prevymis® letermovir MSD prophylaxis of cytomegalovirus (CMV) infection 2017/11/08 8:18.92 - Antivirals, Misc 1 209939
Heplisav-B® hepatitis B vaccine, recombinant Dynavax prevention of hepatitis B (HBV) infection 2017/11/09 80:12 - Vaccines 1 125428
Cinvanti® aprepitant Heron nausea and vomiting associated with chemotherapy 2017/11/09 56:22.32 - Neurokinin-1 (NK1) Receptor Antagonists 3 209296
Abilify Mycite® aripiprazole with ingestible event marker (IEM) Otsuka schizophrenia, bipolar disorder, major depressive disorder 2017/11/13 28:16.08.04 - Atypical Antipsychotics 4 207202
Fasenra® benralizumab AstraZeneca add-on maintenance of severe asthma 2017/11/14 48:10.20 - Interleukin Antagonists 1 761070
Mepsevii® vestronidase alfa-vjbk UltraGenyx mucopolysaccharidosis type VII (MPS VII, Sly syndrome) 2017/11/15 44:00 - Enzymes 1 761047
Hemlibra® emicizumab-kxwh Genentech hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors 2017/11/16 20:28.16 - Hemostatics 1 761083
Juluca® dolutegravir; rilpivirine Viiv HIV-1 infection 2017/11/21 8:18.08.12 - HIV Integrase Inhibitors; 8:18.08.16 - HIV Nonnucleoside Reverse Transcriptase Inhibitors 4P 210192
Impoyz® clobetasol propionate Promius moderate-to-severe plaque psoriasis 2017/11/28 84:06 - Anti-inflammatory Agents 5S 209483
Clenpiq® sodium picosulfate; magnesium oxide; anhydrous citrix acid Ferring colon preparation for colonoscopy 2017/11/28 56:12 - Cathartics and Laxatives 3S 209589
Sublocade® buprenorphine Indivior moderate to severe opioid use disorder 2017/11/30 28:08.12 - Opiate Partial Agonists 3P 209819
Ogivri® trastuzumab-dkst Mylan HER2-overexpressing breast cancer and metastatic gastric/gastroesophageal junction adenocarcinoma 2017/12/01 10:00 - Antineoplastic Agents 761074
Lonhala Magnair® glycopyrrolate Sunovion long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) 2017/12/05 12:08.08 - Antimuscarinics/Antispasmodics 3/4S 208437
Ozempic® semaglutide Novo Nordisk type 2 diabetes mellitus 2017/12/05 68:20.06 - Incretin Mimetics 1S 209637
Xepi® ozenoxacin Ferrer topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes 2017/12/11 84:04.04 - Antibacterials 1S 208945
Admelog® insulin lispro Sanofi Aventis diabetes mellitus 2017/12/11 68:20.08 - Insulins 5S 209196

Drug Classification Changes

 

AHFS Class Change Date Change Description
68:24 - Parathyroid and Antiparathyroid Agents 2017/08/10 Rename class from Parathyroid
68:24.04 - Antiparathyroid Agents 2017/08/10 New subclass
68:24.08 - Parathyroid Agents 2017/08/10 New subclass
26:00 - Cellular and Gene Therapy 2017/09/08 Rename class from Cellular Therapy
26:04 - Cellular Therapy 2017/09/08 New subclass
26:12 - Gene Therapy 2017/09/08 New subclass
68:18 - Gonadotropins and Antigonadotropins 2017/09/15 Rename class from Gonadotropins
68:18.04 - Antigonadotropins 2017/09/15 New subclass
68:18.08 - Gonadotropins 2017/09/15 New subclass
68:16.08 - Antiestrogens 2017/09/20 Revived old class that was retired in 2007
92:18 - Antisense Oligonucleotides 2017/09/20 New subclass
28:56 - Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors 2017/10/16 New subclass

Drug Reassignments

 

Drug Name(s) Active Ingred Change
Date
Old AHFS Class New AHFS Class
Fortical®, Miacalcin® calcitonin 2017/08/10 68:24 - Parathyroid 68:24.04 - Antiparathyroid Agents
Sensipar® cinacalcet 2017/08/10 92:92 - Other Miscellaneous Therapeutic Agents 68:24.04 - Antiparathyroid Agents
Parsabiv® etelcalcetide 2017/08/10 92:92 - Other Miscellaneous Therapeutic Agents 68:24.04 - Antiparathyroid Agents
Tymlos® abaloparatide 2017/08/10 68:24 - Parathyroid 68:24.08 - Parathyroid Agents
Forteo® teriparatide 2017/08/10 68:24 - Parathyroid 68:24.08 - Parathyroid Agents
Natpara® parathyroid hormone 2017/08/10 68:24 - Parathyroid 68:24.08 - Parathyroid Agents
Laviv® azficel-T 2017/09/08 26:00 - Cellular Therapy 26:04 - Cellular Therapy
Provenge® sipuleucel-T 2017/09/08 26:00 - Cellular Therapy 26:04 - Cellular Therapy
Cetrotide® cetrorelix 2017/09/15 92:40 - Gonadotropin-releasing Hormone Antagonists 68:18.04 - Antigonadotropins
Firmagon® degarelix 2017/09/15 10:00 - Antineoplastic Agents 68:18.04 - Antigonadotropins; 10:00 - Antineoplastic Agents
Antagon® ganirelix 2017/09/15 92:40 - Gonadotropin-releasing Hormone Antagonists 68:18.04 - Antigonadotropins
Ovidrel® choriogonadotropin alfa 2017/09/15 68:18 - Gonadotropins 68:18.08 - Gonadotropins
Novarel®, Pregnyl® gonadotropin, chorionic 2017/09/15 68:18 - Gonadotropins 68:18.08 - Gonadotropins
Zoladex® goserelin 2017/09/15 10:00 - Antineoplastic Agents 68:18.08 - Gonadotropins; 10:00 - Antineoplastic Agents
Vantas® histrelin 2017/09/15 10:00 - Antineoplastic Agents 68:18.08 - Gonadotropins; 10:00 - Antineoplastic Agents
Eligard®, Lupron®, Lupron® Depot leuprolide 2017/09/15 10:00 - Antineoplastic Agents 68:18.08 - Gonadotropins; 10:00 - Antineoplastic Agents
Lupaneta® leuprolide; norethindrone 2017/09/15 10:00 - Antineoplastic Agents; 68:32 - Progestins 68:18.08 - Gonadotropins; 68:32 - Progestins; 10:00 - Antineoplastic Agents
Luveris® lutropin alfa 2017/09/15 68:18 - Gonadotropins 68:18.08 - Gonadotropins
Synarel® nafarelin 2017/09/15 68:18 - Gonadotropins 68:18.08 - Gonadotropins
Trelstar®, Triptodur® triptorelin 2017/09/15 10:00 - Antineoplastic Agents 68:18.08 - Gonadotropins; 10:00 - Antineoplastic Agents
Megace® megestrol 2017/09/15 10:00 - Antineoplastic Agents 68:32 - Progestins; 10:00 - Antineoplastic Agents
Nolvadex® tamoxifen 2017/09/15 10:00 - Antineoplastic Agents 68:16.12 - Estrogen Agonist-Antagonists; 10:00 - Antineoplastic Agents
Fareston® toremifene 2017/09/15 10:00 - Antineoplastic Agents 68:16.12 - Estrogen Agonist-Antagonists; 10:00 - Antineoplastic Agents
Arimidex® anastrozole 2017/09/20 10:00 - Antineoplastic Agents 68:16.08 - Antiestrogens; 10:00 - Antineoplastic Agents
Aromsin® exemestane 2017/09/20 10:00 - Antineoplastic Agents 68:16.08 - Antiestrogens; 10:00 - Antineoplastic Agents
Femara® letrozole 2017/09/20 10:00 - Antineoplastic Agents 68:16.08 - Antiestrogens; 10:00 - Antineoplastic Agents
Kisqali®/Femara® Co-Pack (combination) letrozole; ribociclib 2017/09/20 10:00 - Antineoplastic Agents; 10:00 - Antineoplastic Agents 68:16.08 - Antiestrogens; 10:00 - Antineoplastic Agents
Exondys 51® eteplirsen 2017/09/21 92:92 - Other Miscellaneous Therapeutic Agents 92:18 - Antisense Oligonucleotides
Spinraza® nusinersen 2017/09/21 92:92 - Other Miscellaneous Therapeutic Agents 92:18 - Antisense Oligonucleotides
Kynamro® mipomersen 2017/09/21 24:06.92 - Antilipemic Agents, Misc 24:06.92 - Antilipemic Agents, Misc; 92:18 - Antisense Oligonucleotides
Austedo® deutetrabenazine 2017/10/16 28:92 - CNS Agents, Misc 28:56 - Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors
Xenazine® tetrabenazine 2017/10/16 28:92 - CNS Agents, Misc 28:56 - Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors
Ingrezza® valbenazine 2017/10/16 28:92 - CNS Agents, Misc 28:56 - Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors